tradingkey.logo

Niagen Bioscience Inc

NAGE
View Detailed Chart
5.200USD
+0.070+1.36%
Close 02/06, 16:00ETQuotes delayed by 15 min
414.12MMarket Cap
19.83P/E TTM

Niagen Bioscience Inc

5.200
+0.070+1.36%
Intraday
1m
30m
1h
D
W
M
D

Today

+1.36%

5 Days

-13.19%

1 Month

-23.08%

6 Months

-44.68%

Year to Date

-18.24%

1 Year

-8.61%

View Detailed Chart

Key Insights

Niagen Bioscience Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 59 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 15.80.In the medium term, the stock price is expected to trend down.Despite a very weak market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Niagen Bioscience Inc's Score

Industry at a Glance

Industry Ranking
59 / 392
Overall Ranking
178 / 4521
Industry
Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Media Coverage

Last 24 hours
Coverage Level

Very Low
Very High
Negative

Niagen Bioscience Inc Highlights

StrengthsRisks
Niagen Bioscience, Inc., formerly Chromadex Corp., is a global bioscience company. It is engaged in research on nicotinamide adenine dinucleotide (NAD+), an essential coenzyme that is a key regulator of cellular metabolism and is found in every cell of the human body. The Company’s Consumer Products segment provides finished dietary supplement products that contain the Company's proprietary ingredients directly to consumers and distributors and offers NAD+ test kits exclusively to healthcare practitioners. The Ingredients segment develops and commercializes proprietary-based ingredient technologies, including food-grade Niagen and pharmaceutical-grade Niagen, and supplies these ingredients as raw materials to the manufacturers of consumer products and United States FDA-registered 503B outsourcing facilities, respectively. The Analytical Reference Standards and Services segment offers the supply of phytochemical reference standards and other research and development services.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 38.23% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 99.60M.
Turnaround to Profit
The company's performance has turned profitable, with the latest annual net income of USD .
Fairly Valued
The company’s latest PE is 19.83, at a medium 3-year percentile range.
Held by PRFDX
Star Investor PRFDX holds 5.11K shares of this stock.

Analyst Rating

Based on 5 analysts
Buy
Current Rating
15.800
Target Price
+207.99%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Niagen Bioscience Inc News

More news coming soon, stay tuned...

Financial Indicators

EPS

Relevant data have not been disclosed by the company yet.

Total revenue

Relevant data have not been disclosed by the company yet.

Niagen Bioscience Inc Info

Niagen Bioscience, Inc., formerly Chromadex Corp., is a global bioscience company. It is engaged in research on nicotinamide adenine dinucleotide (NAD+), an essential coenzyme that is a key regulator of cellular metabolism and is found in every cell of the human body. The Company’s Consumer Products segment provides finished dietary supplement products that contain the Company's proprietary ingredients directly to consumers and distributors and offers NAD+ test kits exclusively to healthcare practitioners. The Ingredients segment develops and commercializes proprietary-based ingredient technologies, including food-grade Niagen and pharmaceutical-grade Niagen, and supplies these ingredients as raw materials to the manufacturers of consumer products and United States FDA-registered 503B outsourcing facilities, respectively. The Analytical Reference Standards and Services segment offers the supply of phytochemical reference standards and other research and development services.
Ticker SymbolNAGE
CompanyNiagen Bioscience Inc
CEOFried (Robert N)
Websitehttps://www.niagenbioscience.com/
KeyAI